Lung cancer is a difficult malignancy to treat and has a high mortality rate worldwide \[[@b1-jptm-2019-10-12]\]. Smoking was thought to be a major cause of lung cancer, but a large number of lung cancer cases have occurred regardless of smoking status, especially adenocarcinoma (ADC) in women \[[@b2-jptm-2019-10-12],[@b3-jptm-2019-10-12]\]. As female sex hormones were demonstrated to be involved in the differentiation and maturation of fetal lung tissue \[[@b4-jptm-2019-10-12]\], it was suggested that they may also be involved in the development and tissue differentiation of lung cancer. The risk of lung ADC is lower in women with menopause at a relatively young age, and a significant positive correlation has been identified between hormone replacement therapy and the incidence of lung ADC \[[@b5-jptm-2019-10-12],[@b6-jptm-2019-10-12]\], suggesting that female sex hormones may serve certain roles in the development of lung ADC. Mollerup et al. \[[@b7-jptm-2019-10-12]\] demonstrated that estrogen receptor (ER) gene expression was significantly increased in the normal lung tissue of patients with non-small cell lung cancer and non-small cell lung cancer cell lines; the effects of estrogen on cell proliferation were tissue- and cell type-specific. These results suggested a possible role of ERs in lung carcinogenesis \[[@b7-jptm-2019-10-12]\].

Studies on the prognostic effects of female sex hormone receptor expression on lung cancer have exhibited inconsistent results. In a study conducted by Kawai et al. \[[@b8-jptm-2019-10-12]\], patients with non-small cell lung cancer with upregulation of estrogen receptor α (ERα) and downregulation of estrogen receptor β (ERβ) exhibited poor prognoses. Stabile et al. \[[@b9-jptm-2019-10-12]\] demonstrated that high expression of ERβ and low expression of progesterone receptor (PR) were associated with rapid progression of lung cancer. Hsu et al. \[[@b10-jptm-2019-10-12]\] also reported that the prognosis of patients with ERβ-positive lung ADC was poor. By contrast, studies by Schwartz et al. \[[@b11-jptm-2019-10-12]\] and Skov et al. \[[@b12-jptm-2019-10-12]\] demonstrated that the expression of ERβ was associated with good prognosis in non-small cell lung cancer.

The aim of the present study was to analyze the association between female sex hormone receptor expression and clinicopathological characteristics of lung ADC and to determine the clinical significance of female sex hormone receptors and their potential use as prognostic factors.

MATERIALS AND METHODS
=====================

Patients diagnosed with lung ADC at Korea University Guro Hospital (Seoul, Korea) between 2010 and 2012 and treated or followed for \>1 month were included in this study, with the exception of those with a history of cancer or chemotherapy. Hematoxylin and eosin (H&E)-stained glass slides, paraffin tissue blocks, and medical records from 84 patients who underwent surgical resection or biopsy were collected. The medical records included clinical information such as sex, age, smoking history, menopause status, disease relapse, death, and follow-up period, as well as pathological information such as tumor size, stage, histological classification, invasion of vessels/lymph nodes/nerves, and epidermal growth factor receptor (*EGFR*) gene mutation peptide nucleic acid clamping quantitative polymerase chain reaction results. All of the glass slides, paraffin blocks, and clinicopathological information were provided by the Korea University Guro Hospital Biobank, which is a member of the Korea Biobank Network.

In the collected paraffin blocks, representative cancer areas were identified by contrasting with H&E-stained glass slides, and one to three 2-mm cores were obtained and transferred to empty paraffin blocks to construct tissue microarray (TMA) blocks. The TMAs were sectioned in 4-µm slices, mounted on glass slides, and stained with H&E. They were also stained immunohistochemically using a Bond-III automatic stainer (Leica Biosystems Nussloch GmbH, Wetzlar, Germany) or a BenchMark ULTRA automatic stainer (Ventana Medical Systems, Inc., Tucson, AZ, USA). The antibodies used were as follows: antiERα (Ready-To-Use \[RTU\], clone SP1, Ventana Medical Systems, Inc.), anti-ERβ (1:100, clone 14C8, Abcam, Cambridge, UK), anti-PR (RTU, clone 1E2, Ventana Medical Systems, Inc.), anti--androgen receptor (AR; 1:50, clone AR27, Leica Biosystems Nussloch GmbH), anti-EGFR (RTU, clone 3C6, Ventana Medical Systems, Inc.), anti--*EGFR* E746-A750 del (RTU, clone SP111, Ventana Medical Systems, Inc.), and anti--*EGFR* L858R (RTU, clone SP125, Ventana Medical Systems, Inc.).

The results of the immunohistochemical (IHC) staining were assessed independently by two pathologists (J.H.L. and B.K.S.) blinded to clinicopathological information, and the discrepancies were resolved by discussion. ERα, ERβ, and PR staining results were interpreted according to the Allred scoring method, which is a commonly used tool for the determination of female sex hormone receptors in breast cancer, and the staining was considered positive when tumor cell nuclei appeared brown \[[@b13-jptm-2019-10-12]\]. The proportion of stained cells was scored as follows: 0, no positive cells; 1, \<1% positive cells; 2, 1%--10% positive cells; 3, 11%--33% positive cells; 4, 34%--66% positive cells; and 5, 100% positive cells. The staining intensity was scored as follows: 0, cell nuclei were not stained; 1, weakly stained; 2, moderately stained; and 3, intensely stained \[[@b13-jptm-2019-10-12]\]. Subsequently, the sum of the two scores was calculated, and tissue samples with score \>2 were considered positive for ERα, ERβ, and/or PR expression. For AR, cell nuclear staining was considered positive regardless of the intensity of staining. For EGFR, *EGFR* E746-A750 del, and *EGFR* L858R, cell membrane staining was considered positive regardless of the intensity of staining \[[@b14-jptm-2019-10-12]\].

Pearson's chi-square test and Fisher exact test were used to evaluate the association between IHC staining and patient clinicopathological characteristics. Overall survival (OS) was defined as the period between the date of first diagnosis and the date of death or the last follow-up. Progression-free survival (PFS) was defined as the period between the date of first diagnosis and the date when recurrence or progression of lung ADC was confirmed or the last follow-up. A Kaplan-Meier survival curve was used for survival analysis, and the log-rank test was used to determine significant differences. Univariate and multivariate analyses of each factor were performed using the Cox proportional hazards model, and the results were considered statistically significant when the p-value was \<0.05. The Windows version of IBM SPSS ver. 24.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.

Ethics statement
----------------

This study was approved by the Institutional Review Board of Korea University Guro Hospital (approval No. 2018GR0387), and all of the glass slides, paraffin blocks, and clinicopathological information were provided by the Korea University Guro Hospital Biobank, who had collected patients' samples and information with their informed consents.

RESULTS
=======

The detailed clinicopathological information of the study patients is presented in [Table 1](#t1-jptm-2019-10-12){ref-type="table"}. The male-to-female ratio was 43:41; 31 patients had a history of smoking. Of the 41 female patients, 32 were in menopause. According to the 8th edition of the American Joint Committee on Cancer (AJCC) cancer staging manual, stage I or II cancer was identified in 54 patients, whereas advanced stage III or IV cancer was identified in 30 patients. Histological pattern evaluation revealed an acinar pattern in 52 patients, a papillary pattern in 15 patients, a solid pattern in 10 patients, a lepidic pattern in six patients, and a mucinous pattern in one patient. By July 2018, signs of disease recurrence or progression were observed in 36 patients, among which 32 succumbed to disease.

The results of the IHC staining according to clinicopathological features are presented in [Table 2](#t2-jptm-2019-10-12){ref-type="table"}. Among the 84 cases, positive staining for ERα, ERβ, and PR was identified in 39, 71, and 46 cases, respectively. For ERα and PR, the staining was mainly restricted to tumor cell nuclei, whereas for ERβ, the staining was distributed in the nucleus and the cytoplasm. Microscopic images of the representative hormone receptor staining are presented in [Fig. 1](#f1-jptm-2019-10-12){ref-type="fig"}. The expression of ERβ was more frequent in patients ≥65 years compared with patients \<65 years (p= .027), whereas that of PR was only weakly associated with old age and sex (p=.051 and p=.051, respectively). Sex, smoking history, tumor stage, and tumor size were not significantly associated with the expression of female sex hormone receptors, nor did the histological growth pattern exhibit any association with the expression of sex hormone receptors (ERα, p=.566; ERβ, p=.577; PR, p=.857).

Among the 84 cases, positive staining for AR was identified in only one patient, who was a 64-year-old male never-smoker. The associations between the expression of AR and other clinicopathological or molecular characteristics were not further analyzed due to the small number of positive cases.

IHC staining of EGFR, *EGFR* E746-A750 del, and *EGFR* L858R demonstrated that of the 84 cases, 81, 14, and 34 cases were positive for each marker, respectively. No statistically significant associations were identified with clinicopathological features in patients with EGFR- or *EGFR* E746-A750 del--positive tumors. However, *EGFR* L858R--positive tumors were identified to be associated with a younger age (\<65 years vs. ≥65 years, p=.004) and more frequent in women compared with men (p\<.001) and in patients without any smoking history compared with smokers (p=.036) ([Table 2](#t2-jptm-2019-10-12){ref-type="table"}).

The expression levels of female sex hormone receptors were associated with one another (ERα and ERβ, p\<.001; ERα and PR, p=.003; ERβ and PR; p\<.001).

Molecular analysis of *EGFR* mutation status was performed in 51 patients, among which the *EGFR* 19 del mutation was identified in 16 cases (31.4%), the *EGFR* 20 insertion mutation in three cases (5.9%), concurrent *EGFR* 19 del mutation and *EGFR* 20 insertion in one case (2.0%), and the *EGFR* L858R mutation in 18 cases (35.3%). The IHC female sex hormone receptor expression and molecular *EGFR* mutation results appeared to be negatively associated but were not statistically significant ([Table 3](#t3-jptm-2019-10-12){ref-type="table"}).

Kaplan-Meier survival curves and the log-rank test were used to analyze the OS and PFS of the patients. The positive or negative staining of ERα was not significantly associated with OS or PFS. The staining of ERβ and PR also did not impact survival. In addition, the results of IHC staining associated with EGFR exhibited no significant differences in survival. Patients with tumors expressing ERα or ERβ were subdivided into groups according to age, sex, and tumor stage; in the subgroup of patients aged ≥65 years, the ERα-positive group exhibited significantly worse PFS and OS compared with the ERα-negative group ([Fig. 2](#f2-jptm-2019-10-12){ref-type="fig"}).

The results of the univariate analysis demonstrated that OS was significantly associated with sex, tumor stage, and smoking history, whereas PFS was associated with tumor size, stage, smoking history, and menopause status. However, in the multivariate analysis, only sex and tumor stage were significantly associated with OS, and only tumor size was associated with PFS ([Table 4](#t4-jptm-2019-10-12){ref-type="table"}). In the subgroup of patients aged ≥65 years, ERα expression was associated with PFS and OS in the univariate analysis (p=.046 and p=.031, respectively), but not in the multivariate analysis (p=.522 and p=.475, respectively) ([Table 5](#t5-jptm-2019-10-12){ref-type="table"}).

DISCUSSION
==========

The present study investigated the association of female sex hormone receptor expression with clinicopathological features and prognosis in lung ADC. The results demonstrated an association between poor prognosis and ERα expression in the Kaplan-Meier survival analysis with a log-rank test, but the association was not statistically significant in the multivariate analysis. The remaining hormone receptor expression results did not identify statistically significant associations.

ERs are categorized into two subgroups, ERα and ERβ \[[@b15-jptm-2019-10-12]\]. ERα, first identified in 1986, is coded by the *ESR1* gene and mainly distributed in the breast, ovary, and endometrium. ERβ, identified in 1996, is coded by the *ESR2* gene and distributed in various cells and tissues, including the bone, brain, colon, vascular endothelial cells, kidney, lung, ovary, prostate, and testes. In normal lung tissue, ERβ is highly expressed in alveolar and bronchial epithelial cells and involved in the maintenance of the extracellular matrix. In addition, studies using ERβ-knockout mice have reported hypoxia in the mice caused by a decrease in alveolar formation and surfactant secretion \[[@b15-jptm-2019-10-12]\]. ERs contribute to intracellular signaling \[[@b16-jptm-2019-10-12]\]. The complex of estrogen and ER directly acts on the estrogen response element in the nucleus and promotes gene expression through the activation of the RAS/RAF signaling pathway or the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway \[[@b17-jptm-2019-10-12]\].

Studies on the significance of ERs as risk and/or prognostic factors of lung ADC have produced inconsistent results. Certain studies reported that ERα expression in the cytoplasm was associated with poor prognosis \[[@b8-jptm-2019-10-12],[@b18-jptm-2019-10-12]\]. A previous study reported that ERα expression in tumor cell nuclei was associated with good prognosis \[[@b19-jptm-2019-10-12]\], whereas another study identified an association with poor prognosis \[[@b20-jptm-2019-10-12]\]. Studies on the expression of ERβ also produced variable and inconsistent results with different prognosis depending on the sex of the patients and the site of expression in tumor cells \[[@b8-jptm-2019-10-12],[@b12-jptm-2019-10-12],[@b21-jptm-2019-10-12],[@b22-jptm-2019-10-12]\].

The expression patterns and rates of ERs have also been inconsistent in previous studies. The expression rate of ERα has been reported as ranging from 0%--80% and that of ERβ as ranging from 9%--98% \[[@b23-jptm-2019-10-12]\]; these wide ranges may have been due to the various types of antibodies used for evaluation. Antibodies against ERα include mouse monoclonal antibodies 1D5 targeting the amino-terminal domain, 6F11 recognizing the full-length receptor, and rabbit monoclonal antibodies SP1 and HC20, both recognizing the carboxy-terminal domain. A study on ERα expression in lung ADC reported a positive rate of 7.6% with 1D5, 14.1% with 6F11, and 27% with SP1, respectively \[[@b24-jptm-2019-10-12]\]. In another study, the HC20 antibody exhibited a similar positive rate to that of 1D5 \[[@b23-jptm-2019-10-12]\]. Generally, antibodies targeting the amino terminal domain exhibit a positive rate of 0%--40% \[[@b11-jptm-2019-10-12],[@b25-jptm-2019-10-12]\], those against the carboxyl terminal domain exhibit a positive rate of 36%--79% \[[@b22-jptm-2019-10-12],[@b26-jptm-2019-10-12]\], and those recognizing the full-length receptor exhibit a positive rate of 0%--80% \[[@b11-jptm-2019-10-12], [@b27-jptm-2019-10-12],[@b28-jptm-2019-10-12]\]. Antibodies against ERβ also have various types recognizing full-length receptor and splicing variants; a previous study reported that those targeting the amino-terminal exhibited a positive rate of 49%, and the antibody against the carboxyl-terminal exhibited a positive rate of 48%--51%, demonstrating relatively consistent expression, regardless of the target domain, compared with the ERα antibodies \[[@b23-jptm-2019-10-12]\]. The absence of consensus on the criteria for "positivity" in IHC evaluation may also have caused the inconsistent results. Although most of the previous studies used both the proportion of stained cells and the staining intensity, the specific methods were inconsistent. In addition, the criteria for determining the positive results were divided into nuclear and cytoplasmic staining in certain studies, which led to further confusion and discrepancy.

Expression of PR has been demonstrated to increase the secretion of vascular endothelial growth factor (VEGF), which promotes tumor angiogenesis and contributes to tumorigenesis \[[@b29-jptm-2019-10-12],[@b30-jptm-2019-10-12]\]. A previous study in which ER and PR were concurrently administered to lung cancer cell lines revealed that lung tumor cells can produce angiogenetically active VEGF. As these were inhibited by anti-progesterone treatment, the authors concluded that these cancer-promoting effects were mediated by progesterone \[[@b30-jptm-2019-10-12]\]. In chemically-induced lung ADCs in mice, the expression levels of PR and EGFR were associated with each other, as well as with tumor progression \[[@b31-jptm-2019-10-12]\]. However, other studies evaluating the association among the expression of PR, tumorigenesis, and prognosis of lung ADC demonstrated that PR expression was present in 8%--63% of tumors and exhibited no significant association with disease prognosis \[[@b19-jptm-2019-10-12],[@b22-jptm-2019-10-12],[@b32-jptm-2019-10-12]\].

The expression of AR and its relevance to lung ADC have not been well characterized yet. Several studies demonstrated AR expression in non-small cell carcinomas, which suggested the role of AR status in lung cancer \[[@b33-jptm-2019-10-12],[@b34-jptm-2019-10-12]\]. However, the results of studies conducted through this theoretical background were inconsistent. Berardi et al. \[[@b35-jptm-2019-10-12]\] demonstrated a better OS in female non-small cell carcinoma patients with AR expression in carcinoma cells compared to those with tumors showing no AR expression. In contrast, Grant et al. \[[@b36-jptm-2019-10-12]\] demonstrated that AR expression has no association with recurrence or survival in modification with the Ki-67 labeling index. In the present study, only one case expressed AR receptor positivity and therefore cannot be interpreted because of the small number.

EGFR has been identified to be upregulated in \>60% of non-small cell carcinomas \[[@b37-jptm-2019-10-12]\] and is considered to serve an important role in the survival and proliferation of tumor cells. The EGFR signaling pathway is influenced by estrogen-activated ERβ signaling on the cell membrane. Estrogen activates the PI3K/AKT and the MEK/ERK signaling pathways, which are downstream pathways of EGFR activation, and facilitates lung cancer metastasis through epithelial-mesenchymal transition \[[@b38-jptm-2019-10-12],[@b39-jptm-2019-10-12]\]. However, a study evaluating the association between the expression of ERs and *EGFR* mutation in lung ADC failed to demonstrate a significant result \[[@b32-jptm-2019-10-12]\].

In the present study, the expression of EGFR and female sex hormone receptors was evaluated. The IHC evaluation for receptor expression revealed no significant association between female sex hormone receptors and EGFR in lung ADCs. This result was different from the negative association that has generally been observed between the expression of female sex hormone receptors and EGFR in breast cancer \[[@b40-jptm-2019-10-12]-[@b42-jptm-2019-10-12]\]; further studies with a larger sample size may be required to validate this result. The present study also aimed to demonstrate the association between female sex hormone receptor expression and *EGFR* mutation; however, although a negative association was observed, statistical significance could not be achieved.

When the expression patterns of ERα and ERβ were subdivided into groups according to age, sex, or tumor stage, and Kaplan-Meier plotting with the log-rank test was performed, the association between ERβ-expressing tumors in men and better prognosis that was previously reported in some studies \[[@b11-jptm-2019-10-12],[@b12-jptm-2019-10-12]\] was not observed in the present study. PR expression was detected in 54.8% of cases in tumor cell nuclei. PR expression exhibited no significant association with any of the clinicopathological features, and in the survival analysis, no significant differences were observed. The *EGFR* L858R mutation detected by immunohistochemistry was significantly associated with certain clinicopathological features such as age \<65 years, female sex, and no smoking history, which also exhibited well-known associations with molecularly detected *EGFR* mutation.

In conclusion, the present study investigated the expression of the female sex hormone receptors ERα, ERβ, and PR in lung ADCs. The expression of each receptor exhibited associations with certain clinicopathological features and prognostic factors; however, in multivariate analysis, none of the female sex hormone receptors were significantly associated with patient survival.
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![Representative results of immunohistochemical staining. (A) Nuclear staining for estrogen receptor α. (B) Nuclear staining for estrogen receptor β. (C) Nuclear staining for progesterone receptor.](jptm-2019-10-12f1){#f1-jptm-2019-10-12}

![Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) in the age subgroups. (A) Estrogen receptor α (ERα) expression was associated with poor PFS in the age ≥ 65 years subgroup. (B) ERα expression was associated with poor OS in the age ≥ 65 years subgroup. (C) ERα expression was not associated with PFS in the age \< 65 years subgroup. (D) ERα expression was not associated with OS in the age \< 65 years subgroup.](jptm-2019-10-12f2){#f2-jptm-2019-10-12}

###### 

Clinicopathological characteristics of patients studied for female sex hormones receptor expression

  Characteristic       No. (%) (n = 84)
  -------------------- ------------------
  Sex                  
   Male                43 (51.2)
   Female              41 (48.8)
  Age (yr)             63.9 ± 8.8
  Size (cm)            3.1 ± 1.5
  Stage                
   I/II                54 (64.3)
   III/IV              30 (35.7)
  Smoking              
   Never               53 (63.1)
   Ever                31 (36.9)
  Menopause            
   Pre                 9 (22.0)
   Post                32 (78.0)
  Histologic pattern   
   Acinar              52 (61.9)
   Papillary           15 (17.9)
   Solid               10 (11.9)
   Lepidic             6 (7.1)
   Mucinous            1 (1.2)

###### 

The results of IHC staining and clinicopathological characteristics

  Characteristic       No. (n = 84)   ERα positive (%)   p-value   ERβ positive (%)   p-value   PR positive (%)   p-value   *EGFR* 19 positive (%)   p-value   *EGFR* 21 positive (%)   p-value   EGFR positive (%)   p-value
  -------------------- -------------- ------------------ --------- ------------------ --------- ----------------- --------- ------------------------ --------- ------------------------ --------- ------------------- ---------
  Age (yr)                                               .373                         .027                        .051                               .097                               .004                          \> .99
   \< 65               41             17 (41.5)                    31 (75.6)                    18 (43.9)                   4 (9.8)                            23 (56.1)                          40 (97.6)           
   ≥ 65                43             22 (51.2)                    40 (93.0)                    28 (65.1)                   10 (23.3)                          11 (25.6)                          41 (95.3)           
  Sex                                                    .184                         .109                        .051                               .283                               \< .001                       \> .99
   Male                43             23 (53.5)                    39 (90.7)                    28 (65.1)                   9 (20.9)                           9 (20.9)                           41 (95.3)           
   Female              41             16 (39.0)                    32 (78.0)                    18 (43.9)                   5 (12.2)                           25 (61.0)                          40 (97.6)           
  Smoking                                                .237                         .119                        .358                               .479                               .036                          .552
   Never               53             22 (41.5)                    42 (79.2)                    27 (50.9)                   10 (18.9)                          26 (49.1)                          52 (0.98)           
   Ever                31             17 (54.8)                    29 (93.5)                    19 (61.3)                   4 (12.9)                           8 (25.8)                           29 (93.5)           
  Stage                                                  .161                         \>.99                       .102                               \>.99                              .145                          .549
   I--II               54             22 (40.7)                    46 (85.2)                    26 (48.1)                   9 (16.7)                           25 (46.3)                          51 (94.4)           
   III--IV             30             17 (56.7)                    25 (83.3)                    20 (66.7)                   5 (16.7)                           9 (30.0)                           30 (100)            
  Size (cm)                                              .778                         .059                        .335                               .433                               .288                          \> .99
   \< 3                46             22 (47.8)                    42 (91.3)                    23 (50.0)                   9 (19.6)                           21 (45.7)                          44 (95.7)           
   ≥ 3                 38             17 (44.7)                    29 (76.3)                    23 (60.5)                   5 (13.2)                           13 (34.2)                          37 (97.4)           
  Menopause (n = 41)                                     \> .99                       \> .99                      \> .99                             \> .99                             \> .99                        \> .99
   Pre                 9              3 (33.3)                     7 (77.8)                     4 (44.4)                    1 (11.1)                           6 (66.7)                           9 (100)             
   Post                32             13 (40.6)                    25 (78.1)                    14 (43.8)                   4 (12.5)                           19 (59.4)                          31 (96.9)           

Statistically significant (p \< .05).

IHC, immunohistochemical; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor; *EGFR* 19, *EGFR* E746-A750 del; *EGFR* 21, *EGFR* L858R.

###### 

Pearson correlation coefficient between the results of IHC staining and EGFR mutation PNA clamping real-time PCR study

                           ERα                                                      ERβ       PR        *EGFR* 19del mutation                                      *EGFR* 20 ins mutation   *EGFR* L858R mutation
  ------------------------ -------------------------------------------------------- --------- --------- ---------------------------------------------------------- ------------------------ -----------------------
  ERα                      1.00                                                                                                                                                             
  ERβ                      0.398^[a](#tfn1-jptm-2019-10-12){ref-type="table-fn"}^   1.00                                                                                                    
  PR                       0.319^[a](#tfn1-jptm-2019-10-12){ref-type="table-fn"}^   0.405a    1.00                                                                                          
  *EGFR* 19del mutation    --0.103                                                  --0.198   0.013     1.00                                                                                
  *EGFR* 20 ins mutation   --0.227                                                  --0.086   --0.245   0.011                                                      1.00                     
  *EGFR* L858R mutation    --0.257                                                  --0.049   --0.068   --0.499^[a](#tfn1-jptm-2019-10-12){ref-type="table-fn"}^   --0.185                  1.00

IHC, immunohistochemical; EGFR, epidermal growth factor receptor; PNA, peptide nucleic acid; PCR, polymerase chain reaction; ER, estrogen receptor; PR, progesterone receptor.

Statistically significant (p \< .05).

###### 

Cox proportional hazard regression model survival analysis in progression-free survival and overall survival

  Variable               Progression-free survival   Overall survival                                                                                                                                                                                                                                      
  ---------------------- --------------------------- ---------------------------------------------------------- ----------------------- ------------------------------------------------------- ----------------------- ---------------------------------------------------------- ----------------------- -------------------------------------------------------
  Age (≥ 65 yr)          0.717 (0.400--1.287)        .265                                                       \-                      \-                                                      1.592 (0.716--3.537)    .254                                                       \-                      \-
  Female sex             0.569 (0.317--1.021)        .059                                                       \-                      \-                                                      0.257 (0.107--0.620)    .002^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^      0.266 (0.089--0.789)    .017^[b](#tfn3-jptm-2019-10-12){ref-type="table-fn"}^
  Size (≥ 3 cm)          4.006 (2.167--7.405)        \< .001^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^   5.447 (1.664--17.837)   .005^[b](#tfn3-jptm-2019-10-12){ref-type="table-fn"}^   1.925 (0.859--4.310)    .111                                                       \-                      \-
  Stage (III, IV)        3.625 (1.969--6.675)        \< .001^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^   1.049 (0.329--3.349)    .935                                                    5.686 (2.488--12.993)   \< .001^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^   4.325 (1.815--10.306)   .001^[b](#tfn3-jptm-2019-10-12){ref-type="table-fn"}^
  Smoking                1.904 (1.047--3.462)        .035^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^      0.680 (0.113--4.091)    .673                                                    2.933 (1.311--6.559)    .009^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^      0.943 (0.348--2.551)    .908
  Menopause (n = 41)     0.304 (0.114--0.813)        .018^[a](#tfn2-jptm-2019-10-12){ref-type="table-fn"}^      0.803 (0.251--2.565)    .711                                                    0.636 (0.122--3.301)    .590                                                       \-                      \-
  ERα                    0.996 (0.553--1.795)        .990                                                       \-                      \-                                                      1.919 (0.868--4.245)    .107                                                       \-                      \-
  ERβ                    0.642 (0.318--1.294)        .215                                                       \-                      \-                                                      1.341 (0.400--4.500)    .634                                                       \-                      \-
  PR                     0.793 (0.444--1.415)        .432                                                       \-                      \-                                                      1.165 (0.528--2.573)    .705                                                       \-                      \-
  *EGFR* E746-A750 del   0.933 (0.435--2.004)        .860                                                       \-                      \-                                                      0.808 (0.275--2.374)    .699                                                       \-                      \-
  *EGFR* L858R           1.137 (0.630--2.050)        .670                                                       \-                      \-                                                      0.737 (0.324--1.675)    .466                                                       \-                      \-

HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor.

Statistically significant in univariate analysis (p \< .05);

Statistically significant in multivariate analysis (p \< .05).

###### 

Cox proportional hazard regression model survival analysis in progression-free survival and overall survival with the age over 65 subgroup

  Variable               Progression-free survival   Overall survival                                                                                                                                                                                      
  ---------------------- --------------------------- ---------------------------------------------------------- ---------------------- ------ ---------------------------- ------------------------------------------------------- ----------------------- -------------------------------------------------------
  Female sex             0.341 (0.123--0.947)        .039^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^      0.494 (0.171--1.424)   .192   0.159 (0.035--0.718)         .017^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   0.132 (0.020--0.088)    .037^[b](#tfn5-jptm-2019-10-12){ref-type="table-fn"}^
  Size (≥ 3 cm)          6.170 (2.196--17.333)       .001^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^      2.662 (0.725--9.777)   .140   3.208 (1.065--9.660)         .038^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   0.911 (0.212--3.915)    .900
  Stage (III, IV)        6.504 (2.403--17.609)       \< .001^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   2.822 (0.825--9.659)   .098   4.684 (1.521--14.427)        .007^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   5.080 (0.926--27.874)   .061
  Smoking                2.245 (0.906--5.560)        .081                                                       \-                     \-     3.393 (1.130--10.190)        .029^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   0.503 (0.095--2.671)    .420
  ERα                    2.605 (1.017--6.674)        .046^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^      1.383 (0.513--3.733)   .522   3.648 (1.128--11.797)        .031^[a](#tfn4-jptm-2019-10-12){ref-type="table-fn"}^   1.756 (0.374--8.243)    .475
  ERβ                    2.018 (0.267--15.242)       .496                                                       \-                     \-     24.255 (0.006--104217.826)   .455                                                    \-                      \-
  PR                     1.819 (0.687--4.814)        .228                                                       \-                     \-     2.379 (0.655--8.641)         .188                                                    \-                      \-
  *EGFR* E746-A750 del   0.965 (0.349--2.665)        .945                                                       \-                     \-     1.257 (0.384--4.118)         .706                                                    \-                      \-
  *EGFR* L858R           1.159 (0.416--3.224)        .778                                                       \-                     \-     0.982 (0.270--3.574)         .979                                                    \-                      \-

HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor.

Statistically significant in univariate analysis (p \< .05);

Statistically significant in multivariate analysis (p \< .05).
